NasdaqGS:ALNYBiotechs
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback?
If you are wondering whether Alnylam Pharmaceuticals at around US$308 per share still offers value, you are not alone. This article focuses squarely on what that price could mean for long term investors.
The stock has seen a 6.9% decline over the last 7 days and a 16.6% decline over the last 30 days, even though the 1 year and 5 year returns of 16.5% and 105.3% show a very different picture over longer periods.
These moves sit against a backdrop of ongoing interest in RNA interference...